In very rare cases, people who underwent brain surgery as children have developed cerebral amyloid angiopathy in middle age, hinting that those procedures had transmitted seeds of misfolded Aβ. Though ...
The Alzheimer’s genetic hit list just got a little longer. A cadre of scientists, led by Emil Uffelmann, Douglas Wightman, and Danielle Posthuma at VU Amsterdam in the Netherlands, and Ole Andreassen ...
Microglia mean well, but when it comes to clearing tau, they might do more harm than good. That’s according to scientists led by Casper Hoogenraad at Genentech in South San Francisco, California. In ...
Scientists have puzzled over the fact that people who get Alzheimer’s disease at a young age carry a higher burden of tau pathology than do those who get it when they are older. In the November 4 ...
Dozens of rodents have been generated that model various aspects of ALS, like motor impairment or degeneration of motor neurons. No model recapitulates the human disease perfectly. By organizing ...
Application budgets may not exceed $1,300,000 in direct costs in any year unless the application includes a Phase 1 first-in-human clinical trial. For applications including clinical trials, budgets ...
Fewer than 1 percent of amyloid-targeted monoclonal antibodies like lecanemab and donanemab reach their targets in the brain. The excess doses required to make up for this problem raise the risk of ...
Score another one for amyloid immunotherapy. The anti-pyroglutamated amyloid antibody donanemab has posted positive top-line results in the Phase 3 Trailblazer-Alz2 study, according to an Eli Lilly ...
Transferrin-receptor shuttles distribute antibody cargo throughout the parenchyma, steering clear of ARIA-provoking vascular amyloid. Trontinemab is enrolling Phase 3 for early AD, announces plans for ...
At the 19th AD/PD conference, Alzforum reporters wrote 15 summaries of findings across both diseases. From a step toward finally having an α-synuclein PET tracer to a major focus on Trem2 as a drug ...
It has been clear for a while that anti-amyloid antibodies can sweep plaque from the brain, but until now the question of whether this slows cognitive decline has remained hotly contended. Despite ...